EXPLORING THE ANTIDIABETIC, LIPID-LOWERING, AND TISSUE REPAIR BENEFITS OF MULTI-COMPONENT MICROSPHERES IN STREPTOZOTOCIN-INDUCED DIABETIC RATS

Objective: Dapagliflozin, linagliptin, and metformin are extensively utilized either alone or in combination to manage insulin-resistant diabetes. However, the precise administration and effectiveness of their triple combination through a microsphere formulation is yet to be thoroughly explored. This study sets out to explore the antidiabetic and hypolipidemic effects, as well as the histopathological impact of microspheres drug delivery system in streptozotocin (STZ)-administered diabetic rats. Methods: Following an overnight fast, both healthy and diabetic rats were separated into five sets each containing six rats, receiving daily oral treatments for 21 days. Group 1 (control) was administered saline (0.9% NaCl), Group 2 (STZ) received STZ (65 mg/kg through an intraperitoneal injection.), Group 3 (STZ and metformin) received metformin (150 mg/kg), Group 4 (STZ and empagliflozin + linagliptin + metformin) received a tablet combination of these drugs, and Group 5 (STZ and dapagliflozin+linagliptin+metformin) was treated with dapagliflozin (5 mg/kg), linagliptin (5 mg/kg), and metformin microspheres (150 mg/kg). Plasma glucose concentration was monitored weekly, and lipid functions were assessed after 21 days. Histopathological examinations of the pancreas and kidneys were also conducted. Results: The microsphere combination of dapagliflozin, linagliptin, and metformin significantly improved blood glucose levels (109.10±4.13 mg/dL), renal and hepatic functions, and showed beneficial effects on lipid parameters, particularly high-density lipoprotein levels (32.17±3.4 mg/dL), which could lower risk of cardiovascular diseases. Histopathological analysis revealed positive effects on the pancreas and kidneys. A p<0.05 was considered to indicate statistical significance. Conclusion: The microsphere formulation of the triple drug combination demonstrates synergistic antidiabetic properties, enhances body weight, improves lipid profiles, and supports renal and hepatic functions. In addition, it protects against tissue damage to the pancreas and kidneys in STZ-mediated experimental diabetes.

Authors

Institutions

Publication Details

Journal
Asian Journal of Pharmaceutical and Clinical Research
Published
2025-05-07
DOI
https://doi.org/10.22159/ajpcr.2025v18i5.54330
Citations
1
Primary Topic
Advanced Drug Delivery Systems
Type
article
Field-Weighted Citation Impact
0.79
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

EXPLORING THE ANTIDIABETIC, LIPID-LOWERING, AND TISSUE REPAIR BENEFITS OF MULTI-COMPONENT MICROSPHERES IN STREPTOZOTOCIN-INDUCED DIABETIC RATS

Ganesh Prasad Mishra, Surbhi Gupta, Prabhat Singh, Anushree Chauhan
1 citations
Asian Journal of Pharmaceutical and Clinical Research
Advanced Drug Delivery Systems
0.79
article

EXPLORING THE ANTIDIABETIC, LIPID-LOWERING, AND TISSUE REPAIR BENEFITS OF MULTI-COMPONENT MICROSPHERES IN STREPTOZOTOCIN-INDUCED DIABETIC RATS

Ganesh Prasad Mishra, Surbhi Gupta, Prabhat Singh, Anushree Chauhan
article en
1 citations

Abstract

Objective: Dapagliflozin, linagliptin, and metformin are extensively utilized either alone or in combination to manage insulin-resistant diabetes. However, the precise administration and effectiveness of their triple combination through a microsphere formulation is yet to be thoroughly explored. This study sets out to explore the antidiabetic and hypolipidemic effects, as well as the histopathological impact of microspheres drug delivery system in streptozotocin (STZ)-administered diabetic rats. Methods: Following an overnight fast, both healthy and diabetic rats were separated into five sets each containing six rats, receiving daily oral treatments for 21 days. Group 1 (control) was administered saline (0.9% NaCl), Group 2 (STZ) received STZ (65 mg/kg through an intraperitoneal injection.), Group 3 (STZ and metformin) received metformin (150 mg/kg), Group 4 (STZ and empagliflozin + linagliptin + metformin) received a tablet combination of these drugs, and Group 5 (STZ and dapagliflozin+linagliptin+metformin) was treated with dapagliflozin (5 mg/kg), linagliptin (5 mg/kg), and metformin microspheres (150 mg/kg). Plasma glucose concentration was monitored weekly, and lipid functions were assessed after 21 days. Histopathological examinations of the pancreas and kidneys were also conducted. Results: The microsphere combination of dapagliflozin, linagliptin, and metformin significantly improved blood glucose levels (109.10±4.13 mg/dL), renal and hepatic functions, and showed beneficial effects on lipid parameters, particularly high-density lipoprotein levels (32.17±3.4 mg/dL), which could lower risk of cardiovascular diseases. Histopathological analysis revealed positive effects on the pancreas and kidneys. A p<0.05 was considered to indicate statistical significance. Conclusion: The microsphere formulation of the triple drug combination demonstrates synergistic antidiabetic properties, enhances body weight, improves lipid profiles, and supports renal and hepatic functions. In addition, it protects against tissue damage to the pancreas and kidneys in STZ-mediated experimental diabetes.

Asian Journal of Pharmaceutical and Clinical Research
Shobhit University (IN), Swami Vivekanand Subharti University (IN)
Openalex Percentile: Top 28%
Advanced Drug Delivery Systems
0.79
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.